SARS-CoV-2 vaccine development and how Brazil is contributing

Author(s)

Alex I. Kanno ^[1] ; Mayra M.F. Barbosa ; Luana Moraes ; Luciana C.C. Leite ^[4]

Affiliation

^[1] Instituto Butantan. Laboratório de Desenvolvimento de Vacinas - Brasil

^[4] Instituto Butantan. Laboratório de Desenvolvimento de Vacinas - Brasil

• Document type: Journal article
• Source: GENETICS AND MOLECULAR BIOLOGY; v. 44, n. 1 2021-04-02.

Abstract

Abstract The SARS-CoV-2 coronavirus pandemic calls for coordinated efforts by the scientific community for the development of vaccines. The most advanced strategies have focused on modifications of technologies that were already under development for other viruses, such as SARS, MERS, and even Influenza. Classic and new technologies, such as inactivated and attenuated viruses (non-replicative and replicative), DNA and mRNA vaccines, and nanoparticles containing SARS-CoV-2 antigens, are some of the strategies currently investigated. Although there is a very high expectation for the effectiveness of the most advanced vaccine candidates, there are still no established correlates of protection. Previous experience in vaccine development for other pathogens shows that differences in vaccine formulation can result in diverse immune responses and consequently, different protective properties. Therefore the importance of continuing investigations on a broad range of strategies. Expertise in vaccine development in Brazil was refocused to the new coronavirus. Impressive collaboration between institutions will support further developments until we have available a safe, effective, and economically viable vaccine. Established competence and collaborations will allow preparedness for future challenges and can also be used to address local issues as neglected infectious diseases. (AU)

• FAPESP's process: 17/24832-6 - Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma
• Grantee: Luciana Cezar de Cerqueira Leite
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 20/07547-9 - Development of a vaccine against Coronavirus SARS-CoV-2 using a new antigen presenting system
• Grantee: Mayra Mara Ferrari Barbosa
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 17/17218-0 - Implantation of the CRISPR-Cas9 platform in mycobacteria: investigation of ESX-1 system in the immunogenicity of BCG
• Grantee: Luana Moraes
• Support Opportunities: Scholarships in Brazil - Doctorate (Direct)